"instanceType","id","rationale","versionIdentifier","uuid:ID"
"StudyVersion","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","3e196c75-3826-4687-ab8d-67ca475c2c52"
